[go: up one dir, main page]

BR9910864A - Anti-inflammatory compounds for inhibiting cell adhesion - Google Patents

Anti-inflammatory compounds for inhibiting cell adhesion

Info

Publication number
BR9910864A
BR9910864A BR9910864-0A BR9910864A BR9910864A BR 9910864 A BR9910864 A BR 9910864A BR 9910864 A BR9910864 A BR 9910864A BR 9910864 A BR9910864 A BR 9910864A
Authority
BR
Brazil
Prior art keywords
cell adhesion
inhibiting cell
inflammatory compounds
compounds
formula
Prior art date
Application number
BR9910864-0A
Other languages
Portuguese (pt)
Inventor
Andrew O Stewart
Steven A Boyd
David L Arendsen
Pramila Bhatia
Kevin R Condroski
Jennifer C Freeman
Indrani W Gunawardana
Gui-Dong Zhu
Kraig Lartey
Catherine M Mccarty
Nicholas A Mort
Meena V Patel
Michael A Staeger
David M Stout
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of BR9910864A publication Critical patent/BR9910864A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pain & Pain Management (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

"COMPOSTOS ANTI-INFLAMATóRIOS PARA INIBIçãO DE ADERêNCIA CELULAR". Os compostos com a Fórmula (I), são de utilidade para o tratamento de inflamação. Apresenta-se ainda composições farmacêuticas, compreendendo compostos de Fórmula (I), e métodos para inibição/tratamento de doenças inflamatórias num mamífero."ANTI-INFLAMMATORY COMPOUNDS FOR CELLULAR ADHESION INHIBITION". The compounds of Formula (I), are useful for the treatment of inflammation. Pharmaceutical compositions, comprising compounds of Formula (I), and methods for inhibiting / treating inflammatory diseases in a mammal are also disclosed.

BR9910864-0A 1998-06-04 1999-06-03 Anti-inflammatory compounds for inhibiting cell adhesion BR9910864A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9070198A 1998-06-04 1998-06-04
PCT/US1999/012419 WO1999062908A2 (en) 1998-06-04 1999-06-03 Cell adhesion-inhibiting antinflammatory compounds

Publications (1)

Publication Number Publication Date
BR9910864A true BR9910864A (en) 2002-02-05

Family

ID=22223903

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9910864-0A BR9910864A (en) 1998-06-04 1999-06-03 Anti-inflammatory compounds for inhibiting cell adhesion

Country Status (15)

Country Link
EP (1) EP1090009A2 (en)
JP (1) JP2002517396A (en)
KR (1) KR20010052570A (en)
CN (1) CN1332743A (en)
AU (1) AU4231299A (en)
BG (1) BG105109A (en)
BR (1) BR9910864A (en)
CA (1) CA2333770A1 (en)
HU (1) HUP0102366A2 (en)
IL (1) IL139811A0 (en)
NO (1) NO20006157L (en)
PL (1) PL345906A1 (en)
SK (1) SK18542000A3 (en)
TR (1) TR200100189T2 (en)
WO (1) WO1999062908A2 (en)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
WO2000038683A1 (en) * 1998-12-23 2000-07-06 Du Pont Pharmaceuticals Company THROMBIN OR FACTOR Xa INHIBITORS
PL350651A1 (en) 1999-03-09 2003-01-27 Upjohn Co 4-oxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carboxamides as antiviral agents
WO2000075145A1 (en) * 1999-06-03 2000-12-14 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
ME00370B (en) * 1999-06-23 2011-05-10 Sanofi Aventis Deutschland Substituted benzimidazole
US6689883B1 (en) 1999-09-28 2004-02-10 Bayer Pharmaceuticals Corporation Substituted pyridines and pyridazines with angiogenesis inhibiting activity
JP2003522759A (en) * 2000-02-09 2003-07-29 ザ プロクター アンド ギャンブル カンパニー 2-carboxamide-benzimidazoles
US7977333B2 (en) 2000-04-20 2011-07-12 Bayer Healthcare Llc Substituted pyridines and pyridazines with angiogenesis inhibiting activity
WO2003011219A2 (en) 2001-07-27 2003-02-13 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
US6620810B2 (en) 2001-08-30 2003-09-16 Pharmacia & Upjohn Company 4-thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carboxamides as antiviral agents
WO2003020728A1 (en) 2001-08-30 2003-03-13 Pharmacia & Upjohn Company 4-THIOXO-4,7-DIHYDRO-THIENO[2,3-b]PYRIDINE-5-CARBOTHIOAMIDES AS ANTIVIRAL AGENTS
AR038118A1 (en) 2002-01-14 2004-12-29 Upjohn Co COMPOUNDS DERIVED FROM ACID BENCINAMIDE 7-OXO-4,7-DIHIDROTIEN [2,3-B [PIRIDIN-6-CARBOXYLIC 3-REPLACED WHICH ARE USEFUL AS ANTIVIRAL
AR038294A1 (en) 2002-01-14 2005-01-12 Upjohn Co OXOTIENE (3,2-B) PYRIDINCARBOXAMIDS AS ANTIVIRAL AGENTS
AR038117A1 (en) 2002-01-14 2004-12-29 Upjohn Co ANTIVIRAL AGENTS DERIVED FROM 4- OXO-4,7 -DIHYDROFIDE [2,3-B] PIRIDIN-5-CARBOXAMIDA
KR20050006237A (en) * 2002-05-06 2005-01-15 버텍스 파마슈티칼스 인코포레이티드 Thiadiazoles or oxadiazoles and their use as inhibitors of JAK protein kinase
JP2005538118A (en) 2002-08-06 2005-12-15 アストラゼネカ アクチボラグ Condensed pyridine and pyrimidine with TIE2 (TEK) activity
IL154306A0 (en) * 2003-02-05 2003-09-17 Rimonyx Pharmaceuticals Ltd Pharmaceutical compositions comprising thieno [2,3-c] pyridine derivatives and use thereof
JP2007536301A (en) * 2004-05-04 2007-12-13 エフ．ホフマン−ラ　ロシュ　アーゲー Thienopyridazine as an IKK inhibitor
CN1950377A (en) * 2004-05-04 2007-04-18 霍夫曼-拉罗奇有限公司 Thienopyridines as IKK inhibitors
EP1753428A4 (en) * 2004-05-14 2010-09-15 Abbott Lab Kinase inhibitors as therapeutic agents
EP1758895A1 (en) 2004-06-17 2007-03-07 Wyeth a Corporation of the State of Delaware Gonadotropin releasing hormone receptor antagonists
RU2007101509A (en) 2004-06-17 2008-07-27 Уайт (Us) METHOD FOR PRODUCING HORMONE RECEPTOR ANTAGONISTS RELEASING GONADOTROPINE
MX2007001216A (en) 2004-07-30 2007-03-23 Methylgene Inc Inhibitors of vegf receptor and hgf receptor signaling.
JP2008508358A (en) 2004-08-02 2008-03-21 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド Aryl-amino substituted pyrrolopyrimidine multikinase inhibitor compounds
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
CN101084224B (en) * 2004-10-21 2013-12-04 美国陶氏益农公司 Thieno-pyrimidine compounds having fungicidal activity
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
US7674822B2 (en) 2004-11-24 2010-03-09 Wyeth PTP1b inhibitors
AR054416A1 (en) 2004-12-22 2007-06-27 Incyte Corp PIRROLO [2,3-B] PIRIDIN-4-IL-AMINAS AND PIRROLO [2,3-B] PIRIMIDIN-4-IL-AMINAS AS INHIBITORS OF THE JANUS KINASES. PHARMACEUTICAL COMPOSITIONS.
US7534796B2 (en) 2005-02-18 2009-05-19 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
US7582634B2 (en) 2005-02-18 2009-09-01 Wyeth 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7538113B2 (en) 2005-02-18 2009-05-26 Wyeth 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7531542B2 (en) 2005-05-18 2009-05-12 Wyeth Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
CA2608726C (en) 2005-05-20 2013-07-09 Methylgene Inc. Inhibitors of vegf receptor and hgf receptor signaling
BRPI0610322B8 (en) 2005-05-20 2021-05-25 Methylgene Inc vegf receptor and hgf receptor signaling inhibitors and pharmaceutical composition
US7582636B2 (en) 2005-05-26 2009-09-01 Wyeth Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
US8163767B2 (en) 2005-07-14 2012-04-24 Astellas Pharma Inc. Heterocyclic Janus Kinase 3 inhibitors
EP2251341A1 (en) 2005-07-14 2010-11-17 Astellas Pharma Inc. Heterocyclic Janus kinase 3 inhibitors
US8921406B2 (en) 2005-08-21 2014-12-30 AbbVie Deutschland GmbH & Co. KG 5-ring heteroaromatic compounds and their use as binding partners for 5-HT5 receptors
US20070149506A1 (en) 2005-09-22 2007-06-28 Arvanitis Argyrios G Azepine inhibitors of Janus kinases
SI3184526T1 (en) 2005-12-13 2019-03-29 Incyte Holdings Corporation Pyrrolo(2,3-d)pyrimidine derivatives as janus kinase inhibitor
TWI417095B (en) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mglur2-receptors
DK3421471T3 (en) 2006-04-25 2021-06-14 Astex Therapeutics Ltd PURIN AND DEAZAPURIN DERIVATIVES AS PHARMACEUTICAL COMPOUNDS
US8227603B2 (en) 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
AU2007281468B2 (en) 2006-08-02 2012-12-06 Cytokinetics, Incorporated Certain chemical entities, compositions and methods
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
EP2121692B1 (en) 2006-12-22 2013-04-10 Incyte Corporation Substituted heterocycles as janus kinase inhibitors
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
US7851484B2 (en) 2007-03-30 2010-12-14 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
MX2009013402A (en) 2007-06-13 2010-02-24 Incyte Corp Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]py rimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile.
CL2008001709A1 (en) 2007-06-13 2008-11-03 Incyte Corp Compounds derived from pyrrolo [2,3-b] pyrimidine, jak kinase modulators; pharmaceutical composition; and use in the treatment of diseases such as cancer, psoriasis, rheumatoid arthritis, among others.
CA2697399C (en) 2007-09-14 2016-01-19 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
MY152078A (en) 2007-09-14 2014-08-15 Ortho Mcneil Janssen Pharm 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h,1'h-[1,4']bipyridinyl-2'-ones
MX2010003927A (en) 2007-10-11 2010-04-30 Astrazeneca Ab Pyrrolo [2, 3 -d] pyrimidin derivatives as protein kinase b inhibitors.
US8309718B2 (en) 2007-11-16 2012-11-13 Incyte Corporation 4-pyrazolyl-N-arylpyrimidin-2-amines and 4-pyrazolyl-N-heteroarylpyrimidin-2-amines as janus kinase inhibitors
EP2247588B1 (en) 2008-02-26 2016-04-13 Takeda Pharmaceutical Company Limited Fused heterocyclic derivative and use thereof
CN102161663B (en) 2008-03-05 2014-03-19 梅特希尔基因公司 Inhibitors of protein tyrosine kinase activity
CN102026999B (en) 2008-03-11 2014-03-05 因塞特公司 Azetidine and cyclobutane derivatives as JAK inhibitors
US8871753B2 (en) 2008-04-24 2014-10-28 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
AU2009289784B2 (en) 2008-09-02 2012-03-22 Addex Pharma S.A. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
WO2010060589A1 (en) 2008-11-28 2010-06-03 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
US8765727B2 (en) 2009-01-23 2014-07-01 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
AU2010246609B2 (en) 2009-05-12 2013-09-05 Addex Pharma S.A. 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
NZ596053A (en) 2009-05-12 2013-05-31 Janssen Pharmaceuticals Inc 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
WO2010135650A1 (en) 2009-05-22 2010-11-25 Incyte Corporation N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
WO2010135621A1 (en) 2009-05-22 2010-11-25 Incyte Corporation 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
CA2765678A1 (en) 2009-06-22 2010-12-29 Christopher Blackburn Substituted hydroxamic acids and uses thereof
US8624040B2 (en) 2009-06-22 2014-01-07 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
MX2012004180A (en) 2009-10-09 2012-07-17 Incyte Corp Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclo pentylpropanenitrile.
PE20130038A1 (en) 2010-03-10 2013-01-28 Incyte Corp PIPERIDIN-4-IL AZETHYDINE DERIVATIVES AS JAK1 INHIBITORS
SG10201503983QA (en) 2010-05-21 2015-06-29 Incyte Corp Topical Formulation for a JAK Inhibitor
CN102260270A (en) * 2010-05-28 2011-11-30 中国科学院上海药物研究所 N-(2-methylfuran[2,3-d]pyrimidine-4-yl)acrylamide, its preparation method and application
CN103298810B (en) 2010-11-08 2016-03-16 杨森制药公司 The purposes of 1,2,4-triazolo [4,3-a] pyridine derivate and the positive allosteric modulators as MGLUR2 acceptor thereof
EP2643320B1 (en) 2010-11-08 2015-03-04 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
EP2661435B1 (en) 2010-11-08 2015-08-19 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
BR112013012502A2 (en) 2010-11-19 2019-03-06 Incyte Corporation substituted cyclobutyl pyrrolopyridine and derivative pyrrolopyrimidine derivatives as jak inhibitors
EP2640725B1 (en) 2010-11-19 2015-01-07 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
US8778931B2 (en) 2010-12-22 2014-07-15 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
CA2827673C (en) 2011-02-18 2020-10-27 Novartis Pharma Ag Mtor/jak inhibitor combination therapy
MX357447B (en) 2011-04-01 2018-07-10 Astrazeneca Ab Therapeutic treatment.
EP2721028B1 (en) 2011-06-20 2015-11-04 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
KR20140058543A (en) 2011-07-08 2014-05-14 노파르티스 아게 Novel pyrrolo pyrimidine derivatives
CN109316480A (en) 2011-07-13 2019-02-12 赛特凯恩蒂克公司 Combine ALS therapy
WO2013023119A1 (en) 2011-08-10 2013-02-14 Novartis Pharma Ag JAK P13K/mTOR COMBINATION THERAPY
TW201313721A (en) 2011-08-18 2013-04-01 Incyte Corp Cyclohexyl azetidine derivatives as JAK inhibitors
UA111854C2 (en) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS
ES2762250T5 (en) 2011-11-30 2023-01-05 Astrazeneca Ab Combination cancer treatment
WO2013102145A1 (en) 2011-12-28 2013-07-04 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
EP2797416B1 (en) 2011-12-28 2017-08-09 Global Blood Therapeutics, Inc. Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
AR091079A1 (en) 2012-05-18 2014-12-30 Incyte Corp DERIVATIVES OF PIRROLOPIRIMIDINA AND PIRROLOPIRIDINA REPLACED WITH PIPERIDINILCICLOBUTILO AS JAK INHIBITORS
PL2919766T3 (en) 2012-11-15 2021-10-04 Incyte Holdings Corporation PROLONGED RELEASE RUSSOLITINB DOSAGE FORMS
EP3489239B1 (en) 2013-03-06 2021-09-15 Incyte Holdings Corporation Processes and intermediates for making a jak inhibitor
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
AU2014237330A1 (en) 2013-03-15 2015-09-17 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
KR102293060B1 (en) 2013-03-15 2021-08-23 글로벌 블러드 테라퓨틱스, 인크. Compounds and uses thereof for the modulation of hemoglobin
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
JP6426694B2 (en) 2013-03-15 2018-11-21 グローバル ブラッド セラピューティクス インコーポレイテッド Compounds for the modification of hemoglobin and their use
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
JO3368B1 (en) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv 6, 7- dihydropyrazolu [5,1-a] pyrazine-4 (5 hands) -on compounds and their use as negative excretory regulators of Miglore 2 receptors.
LT3030227T (en) 2013-08-07 2020-06-10 Incyte Corporation DURED RELEASE JAK1 INHIBITOR DOSAGE FORMS
JO3367B1 (en) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
EA202092627A1 (en) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. COMPOUNDS AND THEIR APPLICATIONS FOR HEMOGLOBIN MODULATION
AU2014352875B2 (en) 2013-11-22 2019-10-24 CL BioSciences LLC Gastrin antagonists (eg YF476, netazepide) for treatment and prevention of osteoporosis
KR20220038826A (en) 2014-01-21 2022-03-29 얀센 파마슈티카 엔.브이. Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
DK3096790T3 (en) 2014-01-21 2019-10-07 Janssen Pharmaceutica Nv COMBINATIONS INCLUDING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROP GLUTAMATERG SUBTYPE 2 RECEPTOR AND APPLICATION OF THESE
WO2015120133A1 (en) 2014-02-07 2015-08-13 Global Blood Therapeutics, Inc. Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
MA41841A (en) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc ALDEHYDE COMPOUNDS FOR THE TREATMENT OF PULMONARY FIBROSIS, HYPOXIA, AND AUTOIMMUNE AND CONNECTIVE TISSUE DISEASES
BR112018011272A2 (en) 2015-12-04 2018-11-21 Global Blood Therapeutics Inc 2-hydroxy-6 - ((2- (1-isopropyl-1h-pyrazol-5-yl) pyridin-3-yl) methoxy) benzaldehyde dosage regimens
AR108435A1 (en) 2016-05-12 2018-08-22 Global Blood Therapeutics Inc PROCESS TO SYNTHETIZE 2-HYDROXI-6 - ((2- (1-ISOPROPIL-1H-PIRAZOL-5-IL) -PIRIDIN-3-IL) METOXI) BENZALDEHYDE
CN107513067A (en) 2016-06-16 2017-12-26 北京赛林泰医药技术有限公司 Pyrrolopyrimidine compounds containing substituted cyclopenta
US10154992B2 (en) * 2016-07-12 2018-12-18 The Regents Of The University Of California Compounds and methods for treating HIV infection
JOP20190024A1 (en) 2016-08-26 2019-02-19 Gilead Sciences Inc Substituted pyrrolizine compounds and uses thereof
TW202332423A (en) 2016-10-12 2023-08-16 美商全球血液治療公司 Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
AR113922A1 (en) 2017-12-08 2020-07-01 Incyte Corp LOW DOSE COMBINATION THERAPY FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS
MX2020007973A (en) 2018-01-30 2020-12-07 Incyte Corp Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicot inyl)piperidine-4-one).
JP7050165B2 (en) 2018-02-26 2022-04-07 ギリアード サイエンシーズ， インコーポレイテッド Substituted pyrrolidine compounds as HBV replication inhibitors
SI3773593T1 (en) 2018-03-30 2024-08-30 Incyte Corporation TREATMENT OF HIDRADENITIS SUPPURATIVE WITH JAK INHIBITORS
WO2020072377A1 (en) 2018-10-01 2020-04-09 Global Blood Therapeutics, Inc. Modulators of hemoglobin for the treatment of sickle cell disease
US11168093B2 (en) 2018-12-21 2021-11-09 Celgene Corporation Thienopyridine inhibitors of RIPK2
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3903095A (en) * 1972-02-18 1975-09-02 Merck & Co Inc Certain substituted-thieno{8 3,2-c{9 -pyridines
AR208500A1 (en) * 1972-06-14 1977-02-15 Merck & Co Inc PROCEDURE FOR THE PREPARATION OF OXAZOLE (4,5-B) -PYRIDINES DERIVATIVES
FR2334356A1 (en) * 1975-12-10 1977-07-08 Parcor Thieno pyridines and salts - having sedative, antiinflammatory, analgesic and platelet aggregation-inhibiting activity
FR2336132A1 (en) * 1975-12-23 1977-07-22 Parcor Antiinflammatory thieno-indolizines - also with blood platelet aggregation inhibitory activity
FR2411838A1 (en) * 1977-12-19 1979-07-13 Parcor NEW DERIVATIVES OF THIENO (2-3-C) AND (3,2-C) PYRIDINES, THEIR PREPARATION PROCESS AND THEIR THERAPEUTIC APPLICATION
FR2452490A1 (en) * 1979-03-30 1980-10-24 Sanofi Sa 2-Hydroxy-3-aminopropoxy thieno-pyridine derivs. - useful as antiinflammatories, beta blockers and antiarrhythmics for human and veterinary medicine
DE3533331A1 (en) * 1985-09-18 1987-03-26 Heumann Ludwig & Co Gmbh Pyridothiazole derivatives, process for their preparation, and medicaments containing these compounds
US4804658A (en) * 1986-09-15 1989-02-14 G. D. Searle & Co. Imidazopyridine derivatives and pharmaceutical compositions
GB8712747D0 (en) * 1987-05-30 1987-07-01 Pfizer Ltd Therapeutic agents
MY104933A (en) * 1987-09-30 1994-07-30 Pfizer Ltd Platelet activating factor antagonists
US5227384A (en) * 1988-03-14 1993-07-13 G. D. Searle & Co. 5-substituted [4,5-c] imidazopyridines and pharmaceutical use thereof
ATE118006T1 (en) * 1988-03-15 1995-02-15 Searle & Co 1H/3H-(4-(N,N-CYCLOALKYL AND/OR BRANCHED ALKYLCARBOXAMIDO)-BENZYL>IMDAZO(4,5-C>PYRIDINES AS PAF ANTAGONISTS.
CA2012716A1 (en) * 1989-03-22 1990-09-22 Akito Tanaka Thiazole compounds, processes for the preparation thereof and pharmaceutical composition comprising the same
US4988707A (en) * 1989-09-13 1991-01-29 G. D. Searle & Co. Pharmacologically active phenylalkanoyl substituted imidazo (4,5-C) pyridines
US5585492A (en) * 1994-10-11 1996-12-17 G. D. Searle & Co. LTA4 Hydrolase inhibitors
DE69723863T2 (en) * 1996-11-06 2004-04-15 Darwin Discovery Ltd., Slough CHINOLINE AND THEIR THERAPEUTIC USE

Also Published As

Publication number Publication date
BG105109A (en) 2001-11-30
WO1999062908A3 (en) 2000-03-30
TR200100189T2 (en) 2001-05-21
AU4231299A (en) 1999-12-20
SK18542000A3 (en) 2001-12-03
EP1090009A2 (en) 2001-04-11
HUP0102366A2 (en) 2001-11-28
NO20006157D0 (en) 2000-12-04
CA2333770A1 (en) 1999-12-09
NO20006157L (en) 2001-02-02
JP2002517396A (en) 2002-06-18
IL139811A0 (en) 2002-02-10
WO1999062908A2 (en) 1999-12-09
KR20010052570A (en) 2001-06-25
CN1332743A (en) 2002-01-23
PL345906A1 (en) 2002-01-14

Similar Documents

Publication Publication Date Title
BR9910864A (en) Anti-inflammatory compounds for inhibiting cell adhesion
BR9916746A (en) Antiinflammatory compounds that inhibit cell adhesion
BR0112160A (en) Glucocorticoid Selective Anti-Inflammatory Agents
BG105880A (en) Compounds useful as anti-inflammatory agents
BR9907788A (en) Paraglycocorticoid selective anti-inflammatory agents
ATE375334T1 (en) UREA DERIVATIVES AS ANTI-INFLAMMATORY AGENTS
YU39101A (en) Aromatic heterocyclic compounds as antiinflamartory agents
FI973087A7 (en) Cell adhesion inhibitors
DE69824037D1 (en) BETA-ALANINE DERIVATIVES AS CELL ADHESION INHIBITORS
BR0007589A (en) Cell proliferation inhibitors
BG102241A (en) CELLULAR ADHESION INHIBITORS
HK1045306A1 (en) Cell adhesion-inhibiting antiinflammatory compounds
TR200200160T2 (en) Imidazoles and triazoles as anti-inflammatory agents
BR9907847A (en) Selective anti-inflammatory agents for glucocorticoids
BG103193A (en) Cellular adhesion inhibitors
ATE309237T1 (en) AROMATIC HETEROCYCLIC COMPOUNDS AS ANTI-INFLAMMATORY ACTIVES
BR9811099A (en) Urokinase inhibitors
BR9710737A (en) Pentafluorobenzenesulfonamides and the like.
EA200100732A1 (en) ANTI-INFLAMMATORY AND IMMUNOSUPRESSOR COMPOUNDS INHIBITING CELLULAR ADHESION
ATE246184T1 (en) QUINOLINES AND THEIR THERAPEUTIC USE
TR199900157T2 (en) Substituted bisindolylmaleimides for cell proliferation inhibition.
BR9907655A (en) Derivatives of dihydroxyhexanoic acid
BR9907733A (en) Antagonists vla-4
IS6130A (en) Anti-inflammatory treatment for inflammation associated with infection
SE9504662D0 (en) New compounds

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]